A blood RNA transcriptome signature for COVID-19.

Philip Kam WengKwan; Gail BCross; Claire MNaftalin; Bintou AAhidjo; Chee KengMok; FelicFanusi; IntanPermata Sari; Siok ChingChia; Shoban KrishnaKumar; RawanAlagha; +5 more... Sai MengTham; SophiaArchuleta; October MSessions; Martin LHibberd; Nicholas IPaton; (2021) A blood RNA transcriptome signature for COVID-19. BMC medical genomics, 14 (1). 155-. ISSN 1755-8794 DOI: 10.1186/s12920-021-01006-w
Copy

BACKGROUND: COVID-19 is a respiratory viral infection with unique features including a more chronic course and systemic disease manifestations including multiple organ involvement; and there are differences in disease severity between ethnic groups. The immunological basis for disease has not been fully characterised. Analysis of whole-blood RNA expression may provide valuable information on disease pathogenesis. METHODS: We studied 45 patients with confirmed COVID-19 infection within 10 days from onset of illness and a control group of 19 asymptomatic healthy volunteers with no known exposure to COVID-19 in the previous 14 days. Relevant demographic and clinical information was collected and a blood sample was drawn from all participants for whole-blood RNA sequencing. We evaluated differentially-expressed genes in COVID-19 patients (log2 fold change ≥ 1 versus healthy controls; false-discovery rate < 0.05) and associated protein pathways and compared these to published whole-blood signatures for respiratory syncytial virus (RSV) and influenza. We developed a disease score reflecting the overall magnitude of expression of internally-validated genes and assessed the relationship between the disease score and clinical disease parameters. RESULTS: We found 135 differentially-expressed genes in the patients with COVID-19 (median age 35 years; 82% male; 36% Chinese, 53% South Asian ethnicity). Of the 117 induced genes, 14 were found in datasets from RSV and 40 from influenza; 95 genes were unique to COVID-19. Protein pathways were mostly generic responses to viral infections, including apoptosis by P53-associated pathway, but also included some unique pathways such as viral carcinogenesis. There were no major qualitative differences in pathways between ethnic groups. The composite gene-expression score was correlated with the time from onset of symptoms and nasal swab qPCR CT values (both p < 0.01) but was not related to participant age, gender, ethnicity or the presence or absence of chest X-ray abnormalities (all p > 0.05). CONCLUSIONS: The whole-blood transcriptome of COVID-19 has overall similarity with other respiratory infections but there are some unique pathways that merit further exploration to determine clinical relevance. The approach to a disease score may be of value, but needs further validation in a population with a greater range of disease severity.



picture_as_pdf
A blood RNA transcriptome signature for COVID-19.pdf
subject
Published Version
Available under Creative Commons: NC 3.0

View Download

Explore Further

Find work associated with the faculties and division(s):

Find work associated with the research centre(s):

Find work from this publication: